| 000 | 01603 a2200421 4500 | ||
|---|---|---|---|
| 005 | 20250516195137.0 | ||
| 264 | 0 | _c20180124 | |
| 008 | 201801s 0 0 eng d | ||
| 022 | _a2150-1319 | ||
| 024 | 7 |
_a10.1177/2150131914520991 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBener, Abdulbari | |
| 245 | 0 | 0 |
_aComparison of Cost-Effectiveness, Safety, and Efficacy of Rosuvastatin Versus Atorvastatin, Pravastatin, and Simvastatin in Dyslipidemic Diabetic Patients With or Without Metabolic Syndrome. _h[electronic resource] |
| 260 |
_bJournal of primary care & community health _cJul 2014 |
||
| 300 |
_a180-7 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Observational Study | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAtorvastatin _xtherapeutic use |
| 650 | 0 | 4 | _aCost-Benefit Analysis |
| 650 | 0 | 4 |
_aDiabetes Mellitus _xepidemiology |
| 650 | 0 | 4 |
_aDyslipidemias _xdrug therapy |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHypolipidemic Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aLipids _xblood |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMetabolic Syndrome _xepidemiology |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPravastatin _xtherapeutic use |
| 650 | 0 | 4 |
_aRosuvastatin Calcium _xtherapeutic use |
| 650 | 0 | 4 |
_aSimvastatin _xtherapeutic use |
| 650 | 0 | 4 | _aSocioeconomic Factors |
| 700 | 1 | _aDogan, Muzeyyen | |
| 700 | 1 | _aBarakat, Lolwa | |
| 700 | 1 | _aAl-Hamaq, Abdulla O A A | |
| 773 | 0 |
_tJournal of primary care & community health _gvol. 5 _gno. 3 _gp. 180-7 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1177/2150131914520991 _zAvailable from publisher's website |
| 999 |
_c23541171 _d23541171 |
||